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Background: Indigenous residents living in remote communities in Australia’s Northern Territory experience higher
rates of preventable chronic disease and have poorer access to appropriate health services compared to other
Australians. This study compared health outcomes and costs at different levels of primary care utilisation to
determine if primary care represents an efficient use of resources for Indigenous patients with common chronic
diseases namely hypertension, diabetes, ischaemic heart disease, chronic obstructive pulmonary disease and renal
disease.
Methods: This was an historical cohort study involving a total of 14,184 Indigenous residents, aged 15 years and
over, who lived in remote communities and used a remote clinic or public hospital from 2002 to 2011. Individual
level demographic and clinical data were drawn from primary care and hospital care information systems using a
unique patient identifier. A propensity score was used to improve comparability between high, medium and low
primary care utilisation groups. Incremental cost-effectiveness ratios and acceptability curves were used to analyse
four health outcome measures: total and, avoidable hospital admissions, deaths and years of life lost.
Results: Compared to the low utilisation group, medium and high levels of primary care utilisation were associated
with decreases in total and avoidable hospitalisations, deaths and years of life lost. Higher levels of primary care
utilisation for renal disease reduced avoidable hospitalisations by 82-85%, deaths 72-75%, and years of life lost
78-81%. For patients with ischaemic heart disease, the reduction in avoidable hospitalisations was 63-78%, deaths
63-66% and years of life lost 69-73%. In terms of cost-effectiveness, primary care for renal disease and diabetes
ranked as more cost-effective, followed by hypertension and ischaemic heart disease. Primary care for chronic
obstructive pulmonary disease was the least cost-effective of the five conditions.
Conclusion: Primary care in remote Indigenous communities was shown to be associated with cost-savings to
public hospitals and health benefits to individual patients. Investing $1 in primary care in remote Indigenous
communities could save $3.95-$11.75 in hospital costs, in addition to health benefits for individual patients.
These findings may have wider applicability in strengthening primary care in the face of high chronic disease
prevalence globally.
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Australia has made great progress in population health
[1]. From 2001 to 2011, life expectancy at birth increased
by 2.7 years for Australian males and 1.8 years for females
[2]. Unfortunately, life expectancy for the Australian
Aboriginal and Torres Strait Islander population (here-
after referred to as Indigenous) has lagged behind, in
recent estimates, by 10.6 and 9.5 years for males and
females respectively [3]. In the Northern Territory (NT),
the life expectancy gap for the Indigenous population is
40-50% wider than the national figures [4]. It has been es-
timated that chronic diseases contribute 80% of the gap in
life expectancy between Indigenous and non-Indigenous
NT populations [5]. Preventable chronic diseases (PCDs),
including diabetes, ischaemic heart disease (IHD), renal
disease, chronic obstructive pulmonary disease (COPD)
and hypertension are common in remote Indigenous
communities in the NT [6,7].
These diseases are associated with the social determi-
nants of health, including poorer access to appropriate
health services [8]. Indigenous people experience higher
rates and earlier onset of PCD and many patients are diag-
nosed with multiple morbidities [9], adding to the disabil-
ity and mortality burden [10]. In the NT, 30% of residents
of remote Indigenous communities aged over 50 years
have at least three chronic conditions [11]. PCDs are often
characterised by gradual onset, progression over a person’s
lifetime and functional impairment requiring prolonged
assistance [12]. PCDs are costly to manage with chronic
conditions accounting for 60% of the total health and
residential care expenditure in Australia in 2012-13 [13].
In 2008, the Australian Government agreed to targets
to address Indigenous disadvantage, including closing
the gap in life expectancy within a generation (by 2031)
[14]. Access to culturally appropriate, comprehensive
primary care was acknowledged as essential in achieving
this goal [15]. In the words of the chair of the Close the
Gap steering committee for Indigenous health equality:
‘Aboriginal peoples and Torres Strait Islanders have less
access to essential health services than other Australians.
Too often they don’t get the health care they need, when
and where they need it’ [16]. This is often the case in very
small remote communities in the NT where there are few
local services and residents must rely either on periodic
visiting services or travel to access services in larger
centres. Primary care is effective in the prevention, early
detection and management of chronic disease, and in
preventing potentially avoidable hospitalisations (PAH)
and associated morbidity and mortality [17]. Evidence
has shown a strong association between primary care
and better health outcomes, lower costs and greater
equity (reduced disparities) in health across population
subgroups [17-20]. There is some evidence for strength-
ened primary care improving health outcomes and costeffectiveness in remote communities in Australia [21-25].
However, a more comprehensive evidence base is
needed to support greater investments in primary care
for Indigenous people living in remote parts of Australia.
The importance of primary care in remote Indigenous
communities has been recognised and there have been
increases in expenditure in recent years [26,27]. How-
ever, there have also been increases in the population,
rates of PCD and in costs associated with providing pri-
mary care, which together have offset anticipated bene-
fits [11]. In communities where primary care services
are available, funding levels are often insufficient to meet
local health needs [28]. Preventable admissions to hospital
remain high relative to less remote regions. Residents of
remote NT communities experience poorer access to
Medicare and the Pharmaceutical Benefits Scheme (PBS),
the Australian Government funded universal health care
insurance systems. In the 2003/4 financial year, the per
capita Medicare benefit was estimated at $108 for an
Indigenous person in a remote community in the NT,
compared to $413 for other Australians. After inclu-
sion of additional Indigenous specific primary care
funding sources in the NT, including Aboriginal spe-
cific medical services and pharmaceutical allowances,
the per capita expenditure gap persists [29]. Compared
to the national average Medicare and PBS payments,
there was an annual primary care funding gap of $102
million in 2012. In 2011, with additional Indigenous
specific primary care funding the gap was estimated at
$50 million [30]. Sustained investment, proportionate
to need, is required to achieve equitable access to pri-
mary care for Indigenous Australians living in remote
NT communities [11].
The NT covers a large area of Australia, 17% of the
country’s landmass, but contains just 1% of the total popu-
lation [31]. While this makes provision of primary care
services more costly compared to metropolitan areas, the
costs of acute care are also substantially higher [32,33].
Public hospitals provide most of the acute care services to
remote Indigenous residents [33]. Economic evaluation,
including cost-effectiveness studies, can provide important
evidence which can be used to maximise health benefits
through effective use of scarce health resources [34]. The
need for evidence has international significance in relation
to strengthening primary care in the face of a global
chronic disease epidemic. The aim of this study was to
compare the cost-effectiveness of different levels of
primary care utilisation for five chronic diseases, mea-
sured by recurrent costs, total admissions and PAHs,
deaths and years of life lost (YLL).
Methods
A cost effectiveness analysis was applied to an historical
cohort to compare marginal changes in health outcomes
Zhao et al. BMC Health Services Research 2014, 14:463 Page 3 of 9
http://www.biomedcentral.com/1472-6963/14/463and costs between alternative primary care utilisation
groups [35,36]. The study cohort included all Indigenous
residents from geographically defined NT remote local-
ities, who were aged 15 years or over on 1 January 2002
and who attended any of the NT Department of Health’s
54 remote clinics or five public hospitals between 1 January
2002 and 31 December 2011.
Three electronic data sources were used: the primary
care information system (PCIS), hospital admitted pa-
tient data (Caresys), and the government accounting sys-
tem (GAS). A unique client identifier linked individual
records between PCIS and Caresys data. The four health
outcome measures analysed were total hospitalisations,
PAHs, deaths and YLLs [33]. Deaths were identified using
the date of death recorded in PCIS and mode of discharge
from Caresys. YLLs were derived by age at death and
standard life expectancy used in the second Australian
burden of disease and injury study [37].
The study cohort was divided into three groups
according to the annual average number of clinic visits:
low level primary care (<2 visits annually), medium level
primary care [2-11] and high level primary care (≥12). A
chi-square test was used to check the baseline compar-
ability between the control and intervention groups in
terms of key demographic characteristics and number of
chronic diseases. Groups were followed up for hospitali-
sations and deaths.
Hospitalisations and clinic visits related to the five PCDs
were identified using the Australian Refined Diagnosis
Related Groups, Version 4 (AR-DRG) [38] and the
International Classification of Primary Care, Second
Edition (ICPC) (see Table 1) [39]. The International
Statistical Classification of Diseases and Related Health
Problems, Tenth Revision (ICD-10) was used to iden-
tify PAH [40]. PAHs are considered to be admissions
that may have been avoided by providing appropriate
primary care [40]. The data were stratified by high,
medium and low primary care utilisation groups, and
analysed separately for the five PCDs (Table 1). To
minimise data requirements and avoid complex model-
ling of multi-morbidities, each disease was analysed
independently.Table 1 List of disease groups and definitions
Disease group Primary care ICPC
codes
Hospital AR-DRG code
Diabetes T87, T88, T89, T90 F11A, F11B, F13Z, K01Z,
Ischaemic heart
disease
K74, K75, K76 F08A, F08B, F14A, F14B,
F72A, F72B, F05A, F05B,
COPD R91, R95 E65A, E65B, E69A, E69B,
Renal disease U88, U90, U95 L65A, L65B, L67A, L67B, L6
Hypertension F83, K85, K86 F67A, F67B
Notes: AR-DRG = Australian Refined Diagnosis Related Groups; COPD = Chronic obst
Diseases and Related Health Problems; ICPC = International Classification of PrimaryBoth primary care and hospital care were provided
free of charge to public patients. The size and complex-
ity of primary care services varied with the population
of remote communities, but in 2003/4 an “average” re-
mote clinic was situated 275 kilometres (km) from the
nearest hospital (between 100 and 700 km), staffed by
3.4 full time equivalent (FTE) nurses, 1.3 FTE Aboriginal
health workers, 1 FTE receptionist and 0.2 FTE aide
(physical worker). A District Medical Officer (DMO),
located at the nearest major centre, visited these clinics,
on average, 35 times per year. Specialist outreach ser-
vices were provided from the hospitals [32]. Locality
codes were used to define the catchment areas of the
clinics [41]. If there were multiple residential locality
codes for one person, then the residential locality was
determined by the highest frequency of recorded visits
or hospitalisations.
The costing data were sourced from GAS. The cost
estimation for each hospital separation was based on the
NT average AR-DRG cost, which used the bottom-up
method to apportion expenditure based on individual
items of acute care consumption. The cost components
included nursing, medical, allied health, non-clinical sal-
aries, pathology, pharmacy, imaging, supply, emergency,
theatre, critical care, prostheses, hotel services, and other
on-costs. The patient costing model provided data to the
National Hospital Cost Data Collection based on nation-
ally agreed methods for allocating costs [42]. Corporate
overheads, patient travel and major capital costs were
excluded in order to focus on differences in inpatient
treatment costs. The average cost for clinic visits was
estimated using a top-down method by dividing total
remote health care expenditure by the volume of clinic
visits from 2008/9 to 2010/11 [32]. This average cost
estimate was then applied to each patient in the cohort
as a component of the total costs. Incremental total and
average costs per hospitalisation or YLL averted were
estimated by comparing the medium and high utilisation
groups with the low utilisation group. DMOs’ salary and
travel expenses were included in the costing. Capital
expenditure was excluded from the analysis. The average
hospital and clinic visit costs were both converted to thes Hospital ICD-10
codes
K60A, K60B E10-E14
F14C, F12Z, F01A, F01B, F02Z, F66A, F66B, F74Z,
F06A, F06B, F17Z, F18Z
I20-I25
E69C J40-J44, J47
7C, A09A, A09B, L02A, L02B, L60A, L60B, L60C, L61Z N00-N16
I10-I13
ructive pulmonary disease; ICD = International Statistical Classification of
Care.
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health inflation.
Propensity score matching was performed to improve
comparability between primary care utilisation groups in
this observational study [43]. Using logistic regression to
calculate propensity scores enabled us to correct sample
selection bias for key confounders of age, sex and number
of chronic diseases. In the absence of more reliable data,
the number of chronic diseases served as a proxy measure
for the severity of PCDs. Cost-effectiveness was measured
by the ratio between annual incremental mean cost of
medium and high primary care utilisation groups and the
annual incremental mean decrease in those shortfall
health outcomes for those groups relative to the low pri-
mary care utilisation group [44]. A cost-effectiveness
threshold was used as a perceived value when evaluating
cost-effectiveness of medium and high primary care
utilisation [33]. The standard threshold values were
$2915 per separation (NT average cost per AR-DRG)
and $120,000 per statistical life year [45]. The net bene-
fits were calculated by the decrease in shortfall health
outcomes multiplied by the standard threshold values
less costs for medium and high primary care utilisation
[44]. The incremental cost-effectiveness ratio was calcu-
lated as the incremental cost in primary care per unit of
shortfall health outcome averted in comparison to the
low utilisation group, under the assumption that the
high, medium and low utilisation groups were comparable
and the benefit for continued investment was sustainable.
The reciprocal of the incremental cost-effectiveness ratio
was used as the return-on-investment ratio, indicating the
expected marginal benefit per dollar spent on primary care.
The average return-on-investment ratio was weighted
by the number of patients for each PCD. To assess the
uncertainty relating to the cost-effectiveness of primary
care, we calculated cost-effectiveness acceptability
curves [44], which estimate the probability that primary
care is cost-effective in reducing hospital admissions or
YLLs, alongside different values placed on a hospital
separation or a year of life. The effects and benefits were
not discounted.
The NT Department of Health and Menzies School of
Health Research Ethics Committee granted research
ethics approval for this project (Approval Number:
HREC-2012-1849).
Results
A total of 14,184 remote Indigenous patients were eli-
gible to be included in the study, with a majority (70%)
of the cohort aged < 40 years and a minority (44%) were
males. Thirty six percent of the cohort had no primary
care visits and 15% had no hospitalisations. Of the total
number of primary care visits (584,628), 15% were classi-
fied as metabolic, 14% circulatory and 13% urological.Of the total number of hospitalisations (137,395), 55%
were same-day separations and the average length of
stay was three days.
Within the cohort, 49% were in the low primary care
utilisation group, 42% were in the medium primary care
group and 9% were in the high primary care group.
There were no statistically significant differences in age,
sex and number of PCDs between the groups after the
propensity score matching (p >0.05, Table 2). The aver-
age costs were $175 per primary care visit and $2915
per hospitalisation in 2006/7 prices.
Compared to the low utilisation group, the average an-
nual number of hospitalisations per person decreased
with increasing levels of primary care for all five PCDs
(Table 3). Hospitalisations were reduced by 84% in the
medium primary care group and 86% in the high primary
care group for renal disease, 78% and 80% respectively for
diabetes and 73%-78% for hypertension. The reductions in
hospitalisations for IHD and COPD were the lowest
among the five PCDs, but still statistically significant,
ranging from 61% to 75%.
Similarly, compared to the low primary care utilisation
group, PAH rates in the medium and high primary care
groups were 76% and 80% lower, respectively, for diabetes,
63% and 78% for IHD, 70% and 78% for hypertension. For
COPD the reduction in the rate of PAH was the same for
the both medium and high primary care groups (60%).
For renal disease the reduction was greater in the medium
compared to the high utilisation group (85% and 82%).
Death rates in the high and medium groups were
substantially lower than in the control group for all
PCDs. In particular, there were 69% and 75% reduc-
tions in death rate for diabetes, and 72% and 75%
decreases for renal disease.
Compared to the low primary care group, YLLs were
reduced in both the medium and high utilisation groups
for all five PCDs. For diabetes, there were 76% and 80%
reductions in YLL, respectively, and for renal disease there
were 78% and 81% reductions. Overall, reductions in out-
comes measured between the low primary care group and
the medium group were substantial. Differences between
the medium and high primary care groups were marginal.
Differences in total hospitalisation rate, PAH and YLL
rates between medium and high primary care groups were
statistically significant (p < 0.05) for all conditions, with
the exception of renal disease and COPD. There were
no substantial differences in deaths between medium
and high utilisation groups (p > 0.05).
Figure 1 shows the cost-effectiveness acceptability
curves for medium and high level primary care utilisation
groups. As the threshold for willingness-to-pay increased,
the probability that primary care interventions were
more cost-effective also increased, with the medium pri-
mary care group more dominant than the high primary
Table 2 Comparability in age, sex and number of chronic diseases by groups, before and after propensity score
matching
Proportions Low primary care (n = 6987) Medium primary care (n = 5926) High primary care (n = 1271) χ2 significance
Before PSM After PSM Before PSM After PSM Before PSM After PSM Before PSM After PSM
Age
15- 48% 20% 47% 19% 20% 20% 523.3** 2.04 -
30- 24% 23% 25% 25% 23% 23%
40- 14% 26% 15% 27% 27% 27%
50- 7% 18% 8% 17% 17% 17%
60- 7% 13% 5% 12% 13% 13%
Sex
Male 50% 35% 39% 35% 33% 33% 523.3** 2.07 -
Female 50% 65% 61% 65% 67% 67%
Number of chronic diseases
0 63% 10% 43% 10% 10% 10% 2004.8** 11.12 -
1 17% 16% 22% 16% 16% 16%
2 9% 22% 17% 23% 23% 23%
3 7% 28% 13% 30% 31% 31%
4 4% 20% 5% 17% 16% 16%
5 1% 4% 1% 5% 5% 5%
Note: n = number of patients; - p > 0.05; *p < 0.05; **p < 0.01; PSM = propensity score matching.
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cost-effective, followed by diabetes, hypertension and
IHD. Primary care for COPD was the least cost-effective
among the five PCDs (Figure 1). At the aggregate level,
direct hospital savings, defined as the total net benefits
for the five PCDs in 2006/7 prices, amounted to $125
million annually, assuming an additive model for the
five independent PCDs. Across five PCDs, the cost of
saving one hospitalisation was estimated to be in the
range of $134-$404 in the medium level of primary care,
and $425-$1168 in high level primary care (Table 4).
This was far less than the average cost of hospitalisation
($2915) in the NT. It cost $853-$1489 of medium level
of primary care and $2581- $4252 of high level of
primary care to save one YLL. This compared favourably
with the average statistical value of a life year used in
this study ($120,000). Investing in either medium or
high levels of primary care utilisation for all the PCDs in
this study would yield a positive return-on-investment.
Estimates of total average savings for investing $1 in a
medium level of primary care in remote Indigenous
communities could save $11.75 in hospital costs, not
including savings in patient transport. Investing an
additional $1 in a high level of primary care could save
$3.95 in hospital costs. See Table 5.
In a sensitivity analysis, cut-off points of 0 and 6 visits
a year were examined to check if the cut-off points of
primary care frequency would have a major impact onthe outcomes. The results were not substantially differ-
ent from those presented.
Discussion
This large population based observational study using
linked data adds to the growing evidence for the cost
effectiveness of primary care in remote Indigenous com-
munities [19,21,22,25,28], where health needs are high,
access to primary care is poor and the cost of providing
primary care is relatively high, compared to non-remote
areas [32]. The results demonstrate that, within the
study cohort, medium level primary care use is associ-
ated with lower rates of hospitalisation, lower mortality
and fewer YLLs. These better health outcomes resulted
in significant cost savings for governments through
fewer hospitalisations. While investing in primary care
does incur costs, they are modest in comparison with
the net benefits of providing medium level primary care
for the five PCDs. The annual savings of $125 million
did not include savings anticipated from chronic diseases
other than the five PCDs under study, and benefits
anticipated in reductions in YLL.
In a time of fiscal challenge, this evidence is useful to
both policy makers and service planners in guiding re-
source allocation and targeting specific population groups.
Improving access to quality primary care is a vital strategy
in addressing the burden of PCDs and closing the gap in
life expectancy for disadvantaged populations. This can be
Table 3 Annual average hospitalisations, avoidable hospitalisation, death rate and years of life lost by primary health
care utilisation groups, NT remote Indigenous communities, 2002-2011
Annual
average
Primary care utilisation 95% confidence interval Reduction
Low (n = 6987) Medium (n = 5926) High (n = 1271) Low Medium High Medium High
Hospitalisations per person
Diabetes 5 (1421) 1.1 (1892) 1 (772) 4.87-5.11 1.06-1.16 0.89-1.04 78% 80%
IHD 5.9 (612) 2.3 (626) 1.5 (340) 5.69-6.08 2.22-2.47 1.34-1.6 61% 75%
COPD 3.4 (572) 1.3 (657) 1 (322) 3.27-3.58 1.18-1.35 0.92-1.15 62% 71%
Renal Disease 7.7 (1143) 1.2 (1923) 1.1 (826) 7.54-7.87 1.16-1.26 1.06-1.2 84% 86%
Hypertension 4 (1433) 1.1 (1986) 0.9 (832) 3.92-4.13 1.07-1.16 0.88-1.01 73% 78%
PAHs
Diabetes 2.7 0.6 0.5 2.6-2.78 0.6-0.67 0.48-0.59 76% 80%
IHD 4 1.5 0.9 3.8-4.12 1.43-1.63 0.84-1.05 63% 78%
COPD 2 0.8 0.8 1.93-2.17 0.76-0.9 0.66-0.86 60% 60%
Renal Disease 3.4 0.5 0.6 3.31-3.53 0.5-0.57 0.54-0.65 85% 82%
Hypertension 2.3 0.7 0.5 2.19-2.35 0.64-0.71 0.49-0.6 70% 78%
Deaths (per 100)
Diabetes 3.23 0.99 0.80 2.92-3.53 0.85-1.14 0.59-1 69% 75%
IHD 4.71 1.76 1.61 4.16-5.26 1.42-2.09 1.17-2.04 63% 66%
COPD 5.08 1.96 2.04 4.48-5.68 1.62-2.31 1.54-2.54 61% 60%
Renal Disease 4.21 1.18 1.06 3.82-4.59 1.02-1.34 0.83-1.29 72% 75%
Hypertension 3.11 1.28 0.97 2.82-3.41 1.12-1.44 0.75-1.19 59% 69%
YLLs
Diabetes 1.00 0.24 0.20 0.99-1.02 0.23-0.24 0.19-0.21 76% 80%
IHD 1.47 0.46 0.39 1.44-1.5 0.44-0.47 0.37-0.41 69% 73%
COPD 1.32 0.41 0.44 1.29-1.35 0.39-0.42 0.41-0.46 69% 67%
Renal Disease 1.30 0.28 0.25 1.28-1.32 0.27-0.28 0.24-0.27 78% 81%
Hypertension 0.89 0.30 0.23 0.87-0.9 0.29-0.31 0.22-0.24 66% 74%
Notes: n: sample size; COPD: Chronic obstructive pulmonary disease; IHD: Ischemic heart disease; PAH: Potentially avoidable hospitalisations; YLLs: Years of life lost.
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culturally acceptable to local populations in order to en-
sure maximum access [15]. Service models such as com-
prehensive primary health care, provided by remote area
nurses, nurse practitioners and Aboriginal health workers,
which are broad in scope and address the social determi-
nants of health as well as clinical care, prevention and
health promotion are more effective in Indigenous com-
munities [15]. Ensuring quality care through the use of
evidence based standard treatment protocols also contrib-
utes to better health outcomes [46]. Previous studies have
highlighted that for remote areas there are both higher
costs of services and funding gaps which result from a lack
of doctors who are able to access Medicare [29,32]. Ensur-
ing the primary care sector receives an equitable, needs-
based share of funding in order to redress workforce
shortages will contribute to the prevention, early detection
and management of PCDs. While the expansion of appro-
priate, sufficient and high quality services according to
need will address much of the primary care service gaps,as demonstrated in this paper, there may be other factors
that limit the effectiveness of services in the low utilisation
groups. Additional study is needed to identify service
models that meet the specific needs for the population at
the margins of services. Again in the words of the chair of
the Close the Gap steering committee, ‘We should not
accept that Indigenous Australians will end up in hospital
at twice the rate of other Australians, or suffer signifi-
cantly higher rates of heart disease, cancer, kidney failure
or diabetes. In a wealthy country like Australia, such gross
inequality cannot be allowed to continue’.
Limitations: Firstly, we did not have access to data from
Aboriginal Community Controlled Health Organisations
that also provide primary care in some remote NT com-
munities. However, as the geographical areas were defined
by the catchment areas of the clinics, the effects are likely
to be minimal. Secondly, we cannot exclude potential
selection bias as the high level primary care group might
have been relatively sicker than the low utilisation group.
Propensity score matching ensured valid comparisons
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Figure 1 Cost-effectiveness acceptability curves of primary care intervention for preventable chronic diseases, NT remote Indigenous
communities, 2002-2011.
Table 5 Return on investment ratios of primary care in
hospital cost savings by common preventable chronic
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confounders [43]. However, this selection bias is toward
the null, thus, if present would result in more conservative
outcomes. Thirdly, renal dialysis patients dominated hos-
pital costs. When renal related hospital admissions were
excluded, the saving estimates were reduced by 27%. A
fourth limitation was that this study considered each PCD
independently. Comorbidities and interactions between
disease groups were not considered. Fifth, capital costs
were not included in this study as they represent long
term investments. Sixth, patient migration and change in
utilisation through time were beyond the scope of this
study. Finally, we did not quantify the social benefits
resulting from reductions in YLL nor address other
factors that influence PCD including social determinants
of health, governance, and sustainable funding models.Table 4 Incremental costs of primary care interventions
per hospitalisation averted and year of life saved
Medium level of
primary care
High level of
primary care
Average cost
threshold
Per
hospitalisation
averted
$134 - $404 $425 - $1168 $2915*
Per life year
saved
$853 - $1489 $2581 - $4252 $120000#
Note: Medium level: 2-11 visits per year; High level: 12 visits per year or more;
*Average cost per hospitalisation; #the average statistical value of a life
year used.Conclusion
The study demonstrates that increased primary care
utilisation is a cost effective way of improving health
outcomes for Indigenous people living in remote NT
communities. More equitable funding arrangements
for the primary care sector would be a well-considered
investment in the contribution to closing the gap in
Indigenous life expectancy. These findings may have
wider applicability in relation to strengthening primary
care in the face of high chronic disease prevalence
globally.disease
Medium level of primary
care
High level of primary
care
Diabetes $12.95 $4.20
IHD $11.83 $4.61
COPD $7.21 $2.50
Renal
Disease
$21.67 $6.86
Hypertension $9.72 $3.21
Total average $11.75 $3.95
Notes: COPD: Chronic obstructive pulmonary disease; IHD: Ischemic heart disease;
Medium level: 2-11 visits per year, High level: 12 visits per year or more
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